Estimation of Coagulation Factor XIII Activity Based on the Initial Plasma Fibrinogen Level in Trauma
- Conditions
- Coagulation DisorderCoagulation Factor DeficiencyMultiple TraumaCoagulation Defect; Acquired
- Interventions
- Diagnostic Test: fibrinogen plasma concentration, coagulation factor XIII activity
- Registration Number
- NCT03634215
- Lead Sponsor
- Masaryk Hospital Krajská zdravotní a.s.
- Brief Summary
Coagulation factor XIII (FXIII), a plasma transglutaminase, is known as the final enzyme of the coagulation cascade, responsible for a cross-linking of fibrin to strengthen blood clot. It also minimizes fibrin degradation by its cross-linking it with alfa2-antiplasmin molecules. It has been found that similar to plasma fibrinogen level, FXIII activity can be reduced in the early phase of severe trauma. Therefore, its immediate substitution is of potential therapeutic interest in trauma-induced coagulopathy. However, unlike plasma fibrinogen level evaluation, measurement of the FXIII activity is not routinely available. Therefore, targeted substitution of FXIII is practically impossible. The plasma fibrinogen level is routinely measured in severe trauma patients. Based on pathophysiologic assumptions and a limited number of published data we hypothesize that the FXIII activity correlates with fibrinogen level. In such case, indirect FXIII activity prediction by fibrinogen level measurement would be a convenient approach to enable FXIII targeted substitution. Therefore we decided to perform a prospective observational clinical trial to determine whether the low plasma fibrinogen level in severe trauma correlates with decreased FXIII activity.
- Detailed Description
Coagulation factor XIII (FXIII), a plasma transglutaminase, is known as the final enzyme of the coagulation cascade, responsible for a cross-linking of fibrin to strengthen blood clot. It also minimizes fibrin degradation by its cross-linking it with alfa2-antiplasmin molecules. It has been found that similar to plasma fibrinogen level, FXIII activity can be reduced in the early phase of severe trauma. Therefore, its immediate substitution is of potential therapeutic interest in trauma-induced coagulopathy. However, unlike plasma fibrinogen level evaluation, measurement of the FXIII activity is not routinely available. Therefore, targeted substitution of FXIII is practically impossible. The plasma fibrinogen level is routinely measured in severe trauma patients. Based on pathophysiologic assumptions and a limited number of published data we hypothesize that the FXIII activity correlates with fibrinogen level. In such case, indirect FXIII activity prediction by fibrinogen level measurement would be a convenient approach to enable FXIII targeted substitution. Therefore we decided to perform a prospective observational clinical trial to determine whether the low plasma fibrinogen level in severe trauma correlates with decreased FXIII activity.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 357
- a patient with presumed severe trauma admitted to the participating centre
- inflammatory disease
- malignant disease
- pregnancy
- receipt of any fibrinogen / coagulation factor XIII product before blood sampling
- patients on dabigatran
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Multiple Trauma patients fibrinogen plasma concentration, coagulation factor XIII activity -
- Primary Outcome Measures
Name Time Method coagulation factor XIII activity 1 day coagulation factor XIII activity expressed as % of the normal value
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
Fakultní nemocnice Plzen
🇨🇿Plzen, Plzensky Kraj, Czechia
Krajska nemocnice Liberec
🇨🇿Liberec, Liberecký Kraj, Czechia
Masarykova nemocnice v Ústí nad Labem
🇨🇿Ústí Nad Labem, Ústecký Kraj, Czechia